MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
ALT Altimmune
- 8.250
- +0.070+0.86%
Close Dec 20 16:00 ET
- 8.400
- +0.150+1.82%
Post 19:56 ET
586.78MMarket Cap-5.25P/E (TTM)
8.750High8.180Low4.90MVolume8.310Open8.180Pre Close41.07MTurnover6.94%Turnover RatioLossP/E (Static)71.12MShares14.84052wk High4.40P/B582.43MFloat Cap5.27552wk Low--Dividend TTM70.60MShs Float978.000Historical High--Div YieldTTM6.97%Amplitude-1731.000Historical Low8.382Avg Price1Lot Size
About Altimmune Company
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Company Profile
SymbolALT
Company NameAltimmune
Listing DateOct 6, 2005
Founded1997
CEODr. Vipin K. Garg, PhD
MarketNASDAQ
Employees59
Fiscal Year Ends12-31
Address910 Clopper Road,Suite 201S
CityGaithersburg
ProvinceMaryland
CountryUnited States of America
Zip Code20878
Phone1-240-654-1450
Websitehttp://www.altimmune.com
Company Executives
- Name
- Position
- Salary
- Dr. Vipin K. Garg, PhD
- Director, President and Chief Executive Officer
- 5.48M
- Dr. M. Scot Roberts, PhD
- Chief Scientific Officer
- --
- Dr. M. Scott Harris, M.D.
- Chief Medical Officer
- 2.24M
- Raymond M. Jordt, M.B.A.
- Chief Business Officer
- 2.94M
- Gregory L. Weaver
- Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Mitchel Sayare,PhD
- Chairman of the Board
- 119.68K
- Wayne Pisano
- Independent Director
- 108.68K
- Dr. Diane K. Jorkasky, M.D.
- Independent Director
- 95.68K
- Dr. Catherine Angell Sohn, Pharm.D.
- Independent Director
- 273.47K
- Dr. Klaus O. Schafer, M.D.,M.P.H.
- Independent Director
- 104.68K
- Philip L. Hodges
- Independent Director
- 115.68K
- John M. Gill
- Independent Director
- 103.68K
- Andrew Shutterly, M.S.
- Corporate Controller
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
